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ABSTRACT
Lymphocyte antigen 6 complex, locus E (LY6E) has been implicated in the 
malignant progression of various types of cancers; however, the underlying 
mechanism remains unclear. Here, we identified LY6E as an activator of HIF-1 and 
revealed their mechanistic and functional links in malignant tumor growth. The 
aberrant overexpression of LY6E increased HIF-1α gene expression principally at 
the transcription level. This, in turn, led to the expression of the pro-angiogenic 
factors, VEGFA and PDGFB, through decreases in the expression levels of PTEN 
mRNA and subsequent activation of the PI3K/Akt pathway. The LY6E-HIF-1 axis 
functioned to increase tumor blood vessel density and promoted tumor growth in 
immunodeficient mice. LY6E expression levels were significantly higher in human 
breast cancers than in normal breast tissues, and were strongly associated with 
the poor prognoses of various cancer patients. Our results characterized LY6E as 
a novel conductor of tumor growth through its modulation of the PTEN/PI3K/
Akt/HIF-1 axis and demonstrated the validity of targeting this pathway for cancer 
therapy.
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INTRODUCTION
Lymphocyte antigen 6 complex, locus E (LY6E), 
also designated as stem cell antigen 2 (SCA2) and 
thymic shared antigen-1 (TSA-1), is a member of the 
lymphostromal cell membrane Ly6 superfamily [1–3]. 
All Ly6 family members are low-molecular weight (10-
12 kDa) proteins that display limited nucleotide and 
amino acid sequence homologies with one another, but 
commonly have a conserved cysteine-rich cell surface 
domain and are anchored to the cell surface via a glycosil-
phosphatidylinositol (GPI) moiety [4]. Since the cloning 
of the mouse Ly-6E.1 and human LY6E cDNAs in 1986 
and 1993, respectively, extensive efforts have been 
devoted to demonstrating their physiological importance 
in cell-cell adhesion [5], signaling transduction via the 
T cell receptor, and T cell development [6–9]. In the 
field of cancer biology associations with tumorigenicity 
[10–12], cancer stem cell properties [13], and cancer 
metastases [12, 14] have been described. However, it 
currently remains unclear how LY6E promotes malignant 
phenotypes and accelerates tumor growth.
Many solid tumors contain hypoxic regions due 
to an imbalance between the uncontrolled proliferation 
of cancer cells and insufficient formation of a vascular 
network. Cancer cells express many genes in a hypoxia-
inducible factor-1 (HIF-1)-dependent manner in order 
to survive in hypoxic environments [15, 16]. HIF-1 is 
a heterodimeric transcription factor composed of an 
α-subunit (HIF-1α) and β-subunit (HIF-1β), and its activity 
is mainly dependent on the stability of the HIF-1α protein 
[16, 17]. Under normoxic conditions, the proline residues, 
P402 and P564, in the oxygen-dependent degradation 
(ODD) domain of HIF-1α are hydroxylated by prolyl-4-
hydroxylases (PHDs) [18, 19]. This hydroxylation triggers 
the ubiquitination of HIF-1α by a von Hippel-Lindau 
(VHL)-containing E3 ubiquitin ligase, leading to the 
rapid degradation of HIF-1α [18, 19]. In contrast, HIF-1α 
becomes stable under hypoxic conditions because of the 
inactivation of oxygen-dependent hydroxylases, and then 
interacts with HIF-1β [18, 19]. The resultant heterodimer, 
HIF-1, binds to enhancer regions called the hypoxia 
response element (HRE) and induces the expression of a 
series of genes, such as vascular endothelial cell growth 
factor (VEGF) and platelet-derived growth factor B 
(PDGFB), at the transcriptional level [15, 16]. In addition 
to the oxygen-dependent regulation of HIF-1α stability, 
HIF-1 activity was previously shown to be regulated at 
multiple steps, such as the transcriptional initiation [20], 
translational initiation [21], and transactivation [22] of 
HIF-1α. Clinical as well as basic research has shown 
that HIF-1 is associated with angiogenesis, metabolic 
reprogramming, and the invasion and metastasis of cancer 
cells as well as the poor prognoses of cancer patients [15, 
16], which justifies the targeting of HIF-1 itself or its 
upstream activators for cancer therapy [15, 23]. However, 
whereas the oxygen-dependent regulation of HIF-1 
activity has been characterized, the upstream signaling 
pathways that stimulate HIF-1 activity have not yet been 
fully elucidated, which makes it difficult to develop 
strategies that efficiently inhibit HIF-1 activity.
In the present study, we provided a novel insight 
into the regulatory mechanism underlying tumor 
growth via activation of the LY6E-HIF-1 pathway. We 
successfully identified LY6E as a novel upstream activator 
of HIF-1 through a genetic screening strategy we recently 
established [24, 25]. The aberrant expression of LY6E 
was shown to promote tumor growth by activating HIF-1. 
The PTEN/PI3K/Akt pathway was confirmed to be a 
regulator of the LY6E-mediated upregulation of HIF-1 
at the transcription level. LY6E expression levels were 
significantly higher in basal-like subtype human breast 
cancers than in normal breast tissues, and were strongly 
associated with the poor prognoses of various types of 
cancer patients.
RESULTS
LY6E upregulates HIF-1 activity
We recently developed a genetic screening method 
to explore novel activators of HIF-1 [24, 25]. Briefly, 
genetically modified NIH3T3 cells, which exhibited 
antibiotic resistance in a HIF-1-dependent manner, were 
infected with lentiviruses encoding a mouse embryo cDNA 
library, and then cultured in antibiotic-containing medium 
under normoxic conditions. cDNAs were rescued by PCR 
from antibiotic-resistant colonies, with the expectation that 
these cDNAs would have induced antibiotic resistance via 
the activation of HIF-1. Using this approach, we identified 
mouse lymphocyte antigen 6 complex, locus E (Ly6e) as 
a novel candidate activator of HIF-1. We chose to focus 
on the human homolog of LY6E as human and mouse 
LY6E displayed high degrees of amino acid sequence 
homologies with each other.
We performed a luciferase assay using the 5HREp-
luc reporter gene, in which five repeats of HRE functioned 
in the expression of firefly luciferase in a HIF-1-dependent 
manner, to determine whether LY6E induced HIF-1 
activity. The forced expression of LY6E in HeLa cells, 
which originally displayed no detectable LY6E expression 
in Western blotting, resulted in the upregulation of 
5HREp-luc reporter activity under both normoxic and 
hypoxic conditions (Figure 1A and Supplementary 
Figure S1A). The MDA-MB-231 breast cancer cell 
line also exhibited the LY6E-induced upregulation of 
HIF-1 activity (Supplementary Figure S2). In contrast, 
the knockdown of endogenous LY6E in MCF-7 cells, 
a cell line that expresses high levels of endogenous 
LY6E, resulted in a significant decrease in HIF-1 activity 
(Figure 1B and Supplementary Figure S1B). Quantitative 
RT-PCR analyses demonstrated that the overexpression of 
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LY6E led to an increase in the mRNA levels of various 
HIF-1-target genes including VEGF, GLUT1, and CA9 in 
HeLa cells under hypoxic conditions (Figure 1C). Taken 
together, these results showed that LY6E functioned to 
induce HIF-1 activity.
LY6E upregulates HIF-1α gene expression 
principally at the transcriptional level
Although HIF-1 activity is regulated at multiple 
steps, such as the transcriptional initiation, translational 
initiation, and transactivation of HIF-1α, post-translational 
modifications to HIF-1α by PHDs and FIH-1 are known 
to be the most influential in regulating the stability and 
transactivating activity of HIF-1α, respectively. Therefore, 
in order to identify a critical step for the LY6E-mediated 
activation of HIF-1, we first investigated whether LY6E 
increased the expression levels and transactivating activity 
of the HIF-1α protein. Western blotting using HeLa 
cells demonstrated that the overexpression of LY6E led 
to a significant increase in HIF-1α protein levels under 
hypoxic conditions; however, whether this also occurred 
under normoxic conditions was unclear because the basal 
expression levels of HIF-1α were below the detection 
limits (Figure 2A). A human breast cancer cell line, 
MDA-MB-231, exhibited the same result that the forced 
expression of LY6E upregulated HIF-1α expression 
levels (Supplementary Figure S3). The hypoxia-mediated 
induction of HIF-1α expression was strongly inhibited by 
silencing the endogenous LY6E in MCF-7 cells, which 
further strengthened the importance of an increase in 
HIF-1α protein levels for the LY6E-mediated activation 
of HIF-1 (Figure 2B and Supplementary Figure S1B). 
On the other hand, the luciferase assay, which was 
performed to quantify the transactivating activity of HIF-
1α using a fusion gene of the Gal4-DNA binding domain 
(DBD) and the transactivation domain of HIF-1α with a 
P564A mutation (HIF-1α TAD P564A), revealed that the 
transactivating activity of the HIF-1α protein, which was 
enhanced under hypoxic conditions, was not influenced by 
the forced expression of LY6E (Figure 2C).
We then examined how LY6E increased HIF-1α 
protein levels. Since HIF-1α expression levels are known 
to be principally regulated through the hydroxylation of 
P564 in the ODD domain by PHDs, ubiquitination by the 
VHL-containing E3 ubiquitin ligase, and proteolysis, we 
analyzed the influence of the overexpression of LY6E on 
these processes. Western blotting using an anti-hydroxy-
HIF-1α (P564) antibody showed that LY6E did not affect 
the activity of the PHDs (Figure 2D). We performed a 
luciferase assay using the ODD-luc reporter gene, which 
expressed a fusion protein of the ODD domain (HIF-1α 
548-604) with luciferase and, therefore, was useful for 
monitoring HIF-1α stability as luciferase bioluminescence. 
The overexpression of LY6E influenced neither HIF-1α 
stability regardless of the oxygen conditions present 
(Figure 2E) nor the HIF-1α half-life after a reoxygenation 
treatment in vitro (Figure 2F).
We then examined the involvement of LY6E in 
regulating the rate of HIF-1α synthesis at transcriptional 
Figure 1: LY6E upregulated HIF-1 activity. A. HeLa/5HRE-Luc cells were transfected with pcDNA4/LY6E (LY6E) or pcDNA4/
myc-His A (empty vector: EV) and pRL-SV40, cultured under normoxic or hypoxic conditions for the indicated period, and subjected 
to the luciferase assay. B. MCF7 cells transiently transfected with p5HRE-Luc were treated with scramble-siRNA (Scr) or LY6E-siRNA 
(siLYE-1, 2, or 3), cultured under normoxic or hypoxic conditions for the indicated period, and subjected to the luciferase assay. C. HeLa 
cells were transiently transfected with either pcDNA4/LY6E (LY6E) or pcDNA4/myc-His A (EV), cultured under normoxic or hypoxic 
conditions for 24 h, and then subjected to qRT-PCR to quantify the mRNA levels of the indicated genes. Mean ± s.d. n = 3. *P < 0.05, **P 
< 0.001 (Student’s t-test between the 2 indicated samples).
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and translational levels. To determine whether LY6E 
upregulated the rate of HIF-1α translation, we employed 
the HIF-1α 5′UTR-luc reporter gene, which included 
the internal ribosome entry site (IRES) derived from the 
5′UTR of the HIF-1α gene upstream of the luciferase 
coding sequence and, therefore, can be used to monitor 
the rate of the translational initiation of HIF-1α as 
luciferase bioluminescence. The overexpression of LY6E 
significantly increased the rate of translational initiation in 
HeLa cells (Figure 2G); however, this increase appeared to 
be too small to fully explain the marked increase in HIF-1 
activity by LY6E, as observed in Figure 1A. Therefore, we 
tested the influence of LY6E at the transcriptional level by 
utilizing the pHIF-1α promoter-luc reporter plasmid, in 
which the 5′-flanking sequence (5′-FS) from the HIF-1α 
gene was inserted upstream of the firefly luciferase coding 
sequences. The overexpression of LY6E led to a marked 
increase in HIF-1α promoter-luc reporter activity in HeLa 
(Figure 2H). The induction ratio appeared to be sufficient 
to be responsible for the LY6E-mediated increase in 
Figure 2: LY6E upregulated HIF-1α gene expression principally at the transcriptional level. A and B. HeLa (A) or MCF7 
(B) cells were transiently transfected with either pcDNA4/LY6E (LY6E) or pcDNA4/myc-His A (EV) (A) or with either scramble-siRNA 
(Scr) or LY6E-siRNA (siLY6E-1, 2, or 3) (B), cultured under the indicated oxygen conditions, and subjected to western blotting for the 
indicated proteins. The intensity of the bands was quantified using ImageJ and relative HIF-1α expression levels (vs. β-actin) are shown 
in the right panel (A). C. HeLa cells were transiently co-transfected with pG5H1bLuc, pRL-SV40, either pcDNA6/Gal4 or pcDNA6/
Gal4DBD-HIF-1α TAD P564A, and either pcDNA4/LY6E or its empty vector, cultured under normoxic or hypoxic conditions for 24 h, 
and subjected to the luciferase assay. D and E. HeLa (D) or HeLa/ODD-Luc cells (E) were transiently transfected with either pcDNA4/
LY6E or pcDNA4/myc-His A (EV) and with (E) or without (D) pRL-SV40, cultured under the indicated oxygen conditions in the presence 
(D) or absence (E) of 30 μM of the proteasome inhibitor, MG132, and harvested for Western blotting for the indicated proteins (D) or 
luciferase assay (E). F. HeLa/ODD-Luc cells were transfected with pRL-SV40 and either pcDNA4/LY6E (LY6E) or pcDNA4/myc-His 
A (EV), cultured under hypoxic conditions for 48 h, and treated with cycloheximide (10 μg/mL) under normoxic conditions. After the 
reoxygenation treatment for the indicated period, cells were subjected to the luciferase assay. G–K. HeLa (G, H, and J) or MCF7 (I and K) 
cells were transiently transfected with pRL-SV40, either pcDNA4/LY6E or pcDNA4/myc-His A (EV), and either pGL3/HIF-1α 5′UTR-luc 
(G) or pHIF-1α promoter-luc (H and I), treated with (I and K) or without (G, H, and J) scramble-siRNA (Scr) or LY6E-siRNA (siLY6E-1, 
2, or 3), cultured under either normoxic or hypoxic conditions (G-J) or under hypoxic conditions (K), and subjected to the luciferase assay 
(G-I) or qRT-PCR to quantify the mRNA levels of the indicated genes (J and K). L. HeLa/5HRE-Luc cells were transiently co-transfected 
with pRL-SV40 and either pcDNA4/LY6E (LY6E) or pcDNA4/myc-His A (EV), treated with indicated concentrations of Act-D, cultured 
under normoxic or hypoxic conditions, and subjected to the luciferase assay. Relative firefly luciferase activity to renilla luciferase activity 
in LY6E-expressing cells was further normalized by that in EV-transfected cells at each Act-D concentration. Mean ± s.d. n=4. *P < 0.05, 
**P < 0.001 (Student’s t-test between the 2 indicated samples).
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HIF-1 activity. The knockdown of LY6E in MCF-7 cells 
was confirmed to significantly reduce reporter activity 
under both normoxic and hypoxic conditions (Figure 2I). 
Quantitative RT-PCR confirmed that the overexpression 
of LY6E and silencing of endogenous LY6E resulted in 
significant increases and decreases in HIF-1α mRNA 
levels in HeLa and MCF-7 cells, respectively (Figure 
2, J and K). To further confirm the involvement of the 
transcriptional regulation of the HIF-1α gene in the LY6E-
mediated activation of HIF-1, we performed a 5HREp-
luc reporter assay with the transcriptional inhibitor, 
Actinomycin-D (Act-D). To exclude the direct influence 
of the Act-D treatment on the transcription of luciferase 
gene from the reporter and to only evaluate the net 
influence of the Act-D-dependent suppression of HIF-1α 
transcription on the LY6E-mediated activation of HIF-1, 
relative 5HREp-luc activity, which was calculated through 
normalization by renilla luciferase activity, in LY6E-
transfected cells was divided by that in empty vector 
(EV)-transfected cells at each Act-D concentration (Figure 
2L). The luciferase assay revealed that Act-D reduced 
the LY6E-mediated activation of HIF-1, highlighting 
the importance of transcriptional regulation (Figure 2L). 
Taken together, these results indicated that LY6E mainly 
upregulated the transcription of the HIF-1α gene, leading 
to an increase in HIF-1α protein levels and HIF-1 activity.
PTEN and PI3K/Akt signaling pathway are 
involved in LY6E-mediated regulation of HIF-1α 
transcription
We further investigated the molecular mechanisms 
underlying the LY6E-dependent upregulation of the 
transcriptional initiation of the HIF-1α gene. The 
phosphatidylinositol 3-kinase (PI3K)/Akt signaling 
pathway was previously shown to play an important role 
in both the transcriptional [20] and translational initiation 
[21] of the HIF-1α gene; therefore, we examined its 
importance in the LY6E-HIF-1 axis using the PI3K 
inhibitor, LY294002. The luciferase assay using either 
HIF-1α promoter-luc or 5HREp-luc revealed that LY6E-
dependent increases in luciferase bioluminescence in 
HeLa cells were significantly reduced by the inhibitor 
in a dose-dependent manner (Figure 3A and 3B). The 
Figure 3: PTEN and PI3K/Akt signaling pathways were involved in the LY6E-mediated increase in HIF-1α 
transcription. A-F. HeLa (A and C), HeLa/5HRE-Luc (B), or MCF7 (D-F) cells were transfected with either pcDNA4/LY6E (LY6E) or 
pcDNA4/myc-His A (EV) (A-C) either scramble-siRNA (Scr) or Akt-siRNA (C and D), or either scramble-siRNA (Scr) or LY6E-siRNA 
(siLY6E-1, 2, or 3) (E and F), and with (A, C, and D) or without (B, E, and F) pHIF-1α promoter-Luc, cultured under either normoxic or 
hypoxic conditions or under hypoxic conditions if not stated in the presence (A and B) or absence (C-F) of the indicated concentrations 
of LY294002, and subjected to the luciferase assay (A-D), qRT-PCR for PTEN mRNA levels (E), and Western blotting for the indicated 
proteins (F). G-J. HeLa cells were transfected with either pcDNA4/LY6E (LY6E) or pcDNA4/myc-His A (EV) and with (H-J) or without 
(G) either pcDNA4/PTEN-myc (PTEN) or pcDNA4/myc-His A (EV), cultured under normoxic or hypoxic conditions for 24 (G, H left, I, 
and J) or 48 (H right) hours, and subjected to qRT-PCR for PTEN mRNA levels (G and I), Western blotting for the indicated proteins (H), 
or the luciferase assay (J). Mean ± s.d. *P < 0.05, **P < 0.001 (Student’s t-test between the 2 indicated samples).
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knockdown of Akt1 also abrogated the LY6E-mediated 
increase in bioluminescence from the HIF-1α promoter-
luc reporter gene (Figure 3C). Knockdown of endogenous 
expression of Akt1 consistently resulted in the significant 
suppression of HIF-1α promoter activity in MCF7 cells 
(Figure 3D). Taken together, these results indicated that 
the PI3K/Akt signaling pathway mediated the LY6E-
dependent upregulation of HIF-1α transcription and 
resulting activation of HIF-1.
Since it has been well established that PTEN is the 
most influential upstream suppressor of PI3K/Akt signaling 
[26], we next investigated whether PTEN participated in 
the LY6E-mediated regulation of HIF-1 activity. The 
knockdown of endogenous LY6E led to a significant 
increase in PTEN mRNA levels in MCF-7 cells (Figure 3E). 
Western blotting using anti-PTEN, anti-phosphorylated-
Akt, and anti-Akt revealed that the knockdown of LY6E 
in MCF-7 cells increased PTEN levels and decreased 
the phosphorylation of the Akt protein (Figure 3F). On 
the other hand, the overexpression of LY6E reduced the 
mRNA and protein levels of the PTEN gene under both 
normoxic and hypoxic conditions (Figure 3, G and H). 
Exogenously as well as endogenously expressed PTEN 
(PTEN-myc) was down-regulated by the forced expression 
of LY6E at both the mRNA and protein levels, suggesting 
that LY6E reduced PTEN mRNA levels by recognizing the 
coding region of PTEN (Figure 3, H and I). The HIF-1α 
promoter-luc reporter assay was performed following the 
transient transfection of either EV or LY6E and either EV 
or PTEN expression vectors in order to directly determine 
the participation of PTEN expression in the mechanism 
by which LY6E upregulated HIF-1α transcription 
(Figure 3J). Introduction of the PTEN expression vector 
significantly abrogated the HIF-1α promoter-luc reporter 
activity induced by the overexpression of LY6E in HeLa 
cells. Taken together, these results indicated that LY6E 
positively regulated HIF-1α expression at the transcriptional 
initiation level by reducing the levels of PTEN mRNA and 
consequently activating the PI3K/Akt pathway.
LY6E activates HIF-1, induces angiogenesis, and 
consequently accelerates tumor growth
We next investigated whether the LY6E-HIF-1 
axis promoted tumor growth in vivo. We stably 
transfected HeLa/5HRE-Luc cells, which expressed 
luciferase under the control of HIF-1, with either the 
LY6E expression vector (HeLa/5HRE-Luc/LY6E clone 
#16, 19) or its empty vector (HeLa/5HRE-Luc/EV clone 
#2, 6). The forced expression of LY6E was confirmed 
to induce the expression of HIF-1α mRNA and the HIF-
1α protein, upregulate HIF-1 activity, and consequently 
induce the expression of HIF-1-target genes in the 
stable transfectants (Figure 4A-4D and Supplementary 
Figure 4. LY6E activated HIF-1, induced angiogenesis, and consequently accelerated tumor growth. A-D. Stable 
transfectants of HeLa/5HRE-Luc/EV and HeLa/5HRE-Luc/LY6E cells were cultured under either normoxic or hypoxic conditions or under 
hypoxic conditions if not stated, and subjected to qRT-PCR for the indicated genes (A and D), Western blotting for the indicated proteins 
(B), and the luciferase assay. (n = 3). E. Bioluminescent intensity from tumor xenografts with the indicated cells was acquired with the 
IVIS-SPECTRUM imaging system and normalized by each tumor volume 23 days after tumor transplantation into 6 nude mice per one cell 
line (n = 6). F and G. Tumor xenografts of the indicated cells were surgically excised 37 days after cancer cell transplantation and subjected 
to an immunohistochemical analysis using an anti-CD31 antibody (F). Microvessel density detected as CD31-positive cells per one field in 
F was quantified (3 fields in each of 10 representative xenografts, n = 30). H. Growth curves of tumor xenografts after the transplantation 
of HeLa/5HRE-Luc/EV #2, 6 and HeLa/5HRE-Luc/LY6E#16, 19 cells into 10 nude mice per one cell line. Mean ± s.d. *P < 0.05, **P < 
0.01, (Student’s t-test between the 2 indicated samples).
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Figure S4A). Optical imaging experiments confirmed 
that the forced expression of LY6E resulted in high 
levels of HIF-1 activity during tumor growth both in 
vivo and in vitro (Figure 4E and Supplementary Figure 
S4B).
We then examined the influence of LY6E 
on tumor vasculature because we confirmed that 
LY6E significantly induced the expression of pro-
angiogenic factors, such as VEGF and PDGFB 
(Figure 1C and 4D and Supplementary Figure S4A). 
An immunohistochemical analysis against a marker of 
endothelial cells, CD31, demonstrated that microvessel 
density was significantly greater in HeLa/5HRE-Luc/
LY6E tumors than in HeLa/5HRE-Luc/EV tumors 
(Figure 4, F and G and Supplementary Figure S5). The 
tumor growth assay revealed that the forced expression 
of LY6E significantly enhanced the growth of 
HeLa/5HRE-Luc/LY6E tumors more than HeLa/5HRE-
Luc/EV tumors xenografted in immunodeficient mice 
(Figure 4H). These in vivo results collectively indicated 
that the aberrant expression of LY6E positively 
regulated HIF-1 activity, induced angiogenesis, and 
eventually accelerated tumor growth.
Clinical implications of LY6E in human cancer
To confirm our results in human cancers, we 
analyzed the relationship between LY6E expression 
levels and poor prognoses using the PrognoScan database. 
We confirmed that the expression of LY6E positively 
correlated with poor overall survival rates in several 
human cancer patients including lung, bladder, brain, and 
skin cancers (Figure 5A and Supplementary Figure S6). 
The same correlation was confirmed in breast cancer 
patients in another bioinformatics analysis using the 
BreastMark database (Figure 5B).
High expression levels of LY6E have been reported 
in basal-like breast cancer cell lines and have been 
associated with pulmonary breast cancer metastasis [12, 
14]. These findings prompted us to further analyze the 
expression levels of LY6E in basal-like breast cancer 
tissues. The microarray and RNA-seq data sets from 2012 
TCGA [27] showed significantly higher expression levels 
of LY6E in basal-like breast cancer than in surrounding 
normal breast tissues (Figure 5C).
Based on the result that LY6E expression levels were 
inversely correlated with those of PTEN (Figure 3E-3I) and 
Figure 5: Clinical implication of LY6E in human cancer. A. PrognoScan database-based Kaplan-Meier analyses of the overall 
survival of 204 lung (data set: GSE31210; stage I-II lung adenocarcinomas) [46], 165 bladder (data set: GSE13507; histologically diagnosed 
transitional-cell carcinoma) [47], 74 brain (data set: GSE4412-GPL96; grade III and IV gliomas) [48], and 38 skin (data set: GSE19234; 
stage III and IV metastatic melanomas) [49] cancer patients stratified by high (red) and low (blue) LY6E expression levels (lung, high: n = 
141, low: n = 63; bladder, high: n = 19, low: n = 146; brain, high: n = 17, low: n = 57; and skin, high: n = 8, low: n = 30). B. A BreastMark 
database-based Kaplan-Meier analysis of the overall survival of 2091 breast cancer patients stratified by high (blue) and low (red) LY6E 
expression levels. C. LY6E expression levels in basal-like breast cancer tissues (n=98) and normal breast tissues (n=22) from TCGA 2012 
data. D. PrognoScan database-based Kaplan-Meier analyses of the overall survival of the same data set as A stratified by high (red) and low 
(blue) PTEN expression levels.
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with the poor overall survival of cancer patients (Figure 
5, A and B), we hypothesized that expression levels of 
PTEN in malignant tumors should be correlated with the 
poor prognosis of cancer patients. PrognoScan-based 
database analyses on PTEN using the same data set as in 
Figure 5A (GSE31210, GSE13507, GSE4412-GPL-96, and 
GSE19234 for patients with lung, bladder, brain, and skin 
cancers, respectively) actually revealed that patients with 
low intratumoral PTEN expressions exhibited poor overall 
survival (Figure 5D and Supplementary Figure S7).
DISCUSSION
In the present study, we identified LY6E as an 
inducer of HIF-1α expression and defined the novel 
mechanistic and functional linkages of the LY6E-HIF-1 
axis with angiogenesis and growth of malignant solid 
tumors.
Our in vitro studies revealed that the aberrant 
overexpression of LY6E upregulated the transcription 
of the HIF-1α gene by reducing PTEN expression at the 
mRNA level and subsequently activating the PI3K/Akt 
signaling pathway. However, some missing links exist 
in the mechanism. It remains unclear how LY6E reduced 
PTEN mRNA levels. We herein obtained results to show 
that LY6E overexpression decreased the levels of not only 
endogenously, but also exogenously expressed PTEN 
mRNA. PTEN mRNA levels were consistently reported 
to be regulated by some genes, such as IGF2BP1 [28] and 
TGF-β1 through their direct actions on the PTEN coding 
region [29]. Future studies to investigate the possibility 
that LY6E or its downstream factor is involved in the 
downregulation of PTEN at the post-transcriptional level 
are warranted. The mechanisms of actions of the activated 
PI3K/Akt signaling pathway to the HIF-1α gene are 
also still unclear. The PI3K/Akt signaling pathway has 
been shown to positively affect the translational as well 
as transcriptional initiation of the HIF-1α gene. Our 
luciferase assay using the HIF-1α 5′UTR-luc reporter 
gene consistently showed that the translational initiation 
of HIF-1α was significantly upregulated following the 
overexpression of LY6E. Identifying the critical step is 
crucial for fully understanding the molecular mechanisms 
underlying the LY6E-mediated activation of HIF-1, which 
will, in turn, assist in developing inhibitors of the LY6E-
HIF-1 axis for cancer therapy.
Tumor angiogenesis has been closely associated 
with tumor growth, hematogenous metastasis, and the 
poor prognoses of cancer patients [30]. We demonstrated 
that the induction of HIF-1 activity in tumor xenografts 
as a result of the aberrant expression of LY6E enhanced 
angiogenesis and malignant tumor growth. Moreover, 
we confirmed that LY6E expression levels in malignant 
tumors correlated with the poor overall survival of 
patients with various cancers including lung, bladder, 
brain, and skin cancers. The expression levels of LY6E 
were significantly higher in basal-like breast cancer than 
in surrounding normal breast tissues in the TCGA data 
analysis. Taken together, these results justified exploiting 
LY6E as a prognostic marker as well as a therapeutic 
target for cancers.
Basal expression levels of LY6E have been reported 
to be high in normal T cells. Therefore, we would like 
to suggest the possibility that the impact of the aberrant 
overexpression of LY6E on the HIF-1-mediated malignant 
progression demonstrated in the present study can be 
observed only in types of malignant cells other than 
malignant T cells. More importantly, we suggest that it 
might be better to pay attention to the side effects affecting 
normal T cells when we exploit LY6E as a target for 
cancer therapy.
It has not yet been elucidated how LY6E expression 
levels are upregulated in some types of cancers. Previous 
studies provided some suggestions. Five out of 47 
primary breast tumors and 10 out of 18 breast cancer cell 
lines were reported to have a high level copy number 
of the chromosome 8q24 region. This amplicon, which 
extends from 139.3 to 144.8 Mb (8q24.3), encodes 8 
genes from LY6 family members including LY6E [31]. 
Furthermore, type I interferons, such as IFN-α, have 
been reported to strongly enhance LY6E mRNA levels in 
human cancer cells because of the presence of the IFN-
α-stimulated response element (ISRE) on the upstream 
sequence of LY6E [32–34]. On the other hand, GATA3, 
the low expression of which has been linked to the 
malignant progression of breast cancers, has been shown 
to negatively regulate LY6E expression in breast cancer 
cells [14]. Based on accumulating evidence, elucidating 
the mechanisms underlying the aberrant overexpression 
of LY6E in cancer cells will provide an insight into the 
development of rational strategies that target the LY6E-
HIF-1 axis for cancer therapy.
MATERIALS AND METHODS
Cell culture and reagents
NIH/3T3, HeLa, MCF7, and MDA-MB-231 cell 
lines were purchased from the American Type Culture 
Collection and maintained in 10% FBS-Dulbecco’s 
modified Eagle’s medium. Cells were incubated in a 
well humidified incubator with 5% CO2 and 95% air 
for the normoxic condition. Cells were incubated in the 
Bactron Anaerobic Chamber, BACTLITE-2 (Sheldon 
Manufacturing, Comelius, OR) and in RUSKIN INVIVO2 
500 (The Baker Company, Sanford, FL) for the hypoxic 
condition at <0.02% O2 and 1% O2, respectively. Stock 
solutions of LY294002 (Cell signaling), Actinomycin-D 
(Act-D), and cycloheximide (Nacalai Tesque) were 
prepared in DMSO (10 or 20 μM, 10 or 20 ng/mL, and 
10 mg/mL, respectively). Double strand RNAs for the 
transient silencing of LY6E (silencer Select Validated 
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siRNA, Cat. No. SR302746A: 5′-cccagaaggcgucaaugu
uggugug-3’, SR302746B: 5′-gcuuuggugccucaaauaaaua
cag-3’, and SR302746C: 5′-gcuccgaccaggacaacuacugc
gu-3’) and the universal scrambled negative control (Cat. 
No. SR30004: sequence information is not disclosed) were 
purchased from Origene (Origene Technologies, Inc., 
Rockville, MD).
Plasmid constructs
To construct pcDNA4/LY6E, the cDNA encoding 
human LY6E gene was amplified from the cDNA of HeLa 
cells and inserted between the BamHI and XhoI sites 
of pcDNA4/myc-His A (Invitrogen, Carlsbad, CA). To 
construct pEF/SV40p-ODD-Luc encoding the ODD-Luc 
reporter gene, the DNA fragment encoding the SV40p-
ODD-luc reporter gene was prepared by digesting pGL3/
ODD-Luc with KpnI and XbaI, and inserted between 
the corresponding sites of pEF/myc/cyto (Invitrogen). 
The plasmid p5HRE-Luc was constructed as described 
previously [35]. To construct pHIF-1α promoter-luc and 
pGL3/HIF-1α 5′UTR-luc, the DNA fragments of the HIF-
1α promoter (-572 - +32) and HIF-1α 5′UTR (+1 - +284) 
were amplified from the genomic DNA of HeLa cells 
and inserted between the BglII and HindIII sites and also 
between the HindIII and NcoI sites of the pGL3 promoter 
vector (Promega), respectively. To construct pcDNA4/
PTEN-myc, the cDNA encoding the human PTEN gene 
was amplified from the cDNA of MCF7 cells and inserted 
between the XhoI and XbaI sites of pcDNA4/myc-His A 
(Invitrogen). To construct pcDNA6/Gal4DBD-HIF-1α 
TAD P564A, which expresses a fusion protein of Gal4 
DBD and HIF-1α TAD with a P564A mutation, a DNA 
fragment encoding Gal4 DBD prepared from the GalA 
expression vector and that encoding HIF-1α CTAD P564A 
(HIF-1α 531a.a - 826a.a. with P564A mutation) were 
inserted into the HindIII and EcoRI sites and between the 
EcoRI and XhoI sites of pcDNA6/V5-His A (Invitrogen), 
respectively. The plasmid pG5H1bLuc, containing five 
Gal4-binding sites upstream of the adenovirus E1b 
promoter and firefly luciferase CDS, was constructed as 
described previously [22, 36].
Stable transfectants
HeLa and MDA-MB-231 cells were stably 
transfected with pEF/SV40p-ODD-Luc (for HeLa/
ODD-Luc) [37], p5HRE-Luc (for HeLa/5HRE-Luc and 
MDA-MB-231/5HRE-Luc) [35, 38], or a combination of 
p5HRE-Luc and either pcDNA4/myc-His A (Invitrogen; 
for HeLa/5HRE-Luc/EV [clone #2, 6]) or pcDNA4/LY6E 
(for HeLa/5HRE-Luc/LY6E [clone #16, 19]). Cells were 
then cultured for 10-14 days in culture medium containing 
the corresponding antibiotic to select antibiotic-resistant 
stable transfectants. The resultant colonies were isolated 
and established as clones. Representative clones showing 
expected and reasonable activities were used in the present 
study.
Screening of LY6E as an upstream activator of 
HIF-1
LY6E was isolated from the mouse embryo cDNA 
library (Clontech) as a potential activator of HIF-1 through 
genetic screening experiments [24, 25].
Luciferase assay and western blotting
Twenty-four hours after cells (2 × 104 cells/well 
in a 24-well plate for the luciferase assay and 2 × 105 
cells/well in a 6-well plate for Western blotting) were 
transfected with the indicated plasmids, they were treated 
under normoxic (20% O2) and hypoxic (<0.02 or 1% O2) 
conditions for the luciferase assay and Western blotting, 
respectively, for the indicated periods, and harvested in 
100 μL Passive Lysis Buffer (Promega) for the luciferase 
assay or 150 μL Cell Lytic Buffer (Sigma-Aldrich) for 
western blotting. The luciferase assay was performed 
using the dual luciferase assay kit according to the 
manufacturer’s instructions (Promega). The plasmid, 
pRL-SV40 (Promega), was used as an internal control 
to calculate relative luciferase activity. Western blotting 
was performed using anti-HIF-1α (BD Bioscience for 
human HIF-1α, Cat# 610959), anti-LY6E (Abnova Cat# 
H00004061-D01P), anti-PTEN (Cell Signaling Cat# 
9559), anti-hydroxy-HIF-1α (Pro564; Cell Signaling), 
anti-β-actin (BioVision Cat# 3598-100), anti-Akt (Cell 
Signaling Cat# 9272), and anti-phospho-Akt (Ser473) 
(Cell Signaling Cat# 9271) antibodies as the primary 
antibodies, anti-mouse and anti-rabbit IgG horseradish 
peroxidase-linked whole antibodies (GE Healthcare) 
as the secondary antibodies, and the ECL Plus Western 
Blotting Detection system (GE Healthcare) for detection 
according to the manufacturer’s instructions.
qRT-PCR
After cells (2 × 105 cells/well in a 6-well-plate) 
were treated as described in the figure legends, total RNA 
was extracted and subjected to reverse transcription as 
described previously [24, 25]. The mRNA level of the 
indicated gene was quantified by the qRT-PCR technique 
using the Thermal Cycler Dice Real Time System (TP-
800; Takara Bio) with the SYBR Premix Ex Taq kit 
(Takara Bio) and commercial primers (TaKaRa Primer Set 
ID HA074624 for HIF-1α mRNA, HA160790 for VEGFA 
mRNA, HA154269 for PDGF-β mRNA, HA126121 for 
GLUT1 mRNA, HA176356 for CA9 mRNA, HA112155 
for PTEN mRNA, HA139090 for LY6E mRNA, 
HA067803 for human β-actin mRNA) according to the 
manufacturer’s instructions. β-actin mRNA levels were 
used as a normalizer.
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In vivo experiments
Cancer cell suspensions (100 μL of 3 × 105 cells 
in PBS) were subcutaneously transplanted into the 
right hind legs of athymic nude mice (BALB/c nu/nu: 
SLC, Japan). Tumor volumes were calculated as 0.5 × 
length × width2, and compared with the initial value 
to calculate relative tumor volume. Representative 
images of tumor-bearing mice were taken with the IVIS 
spectrum in vivo imaging system (Caliper) as described 
previously [35, 38–42].
Immunohistochemical analysis
Frozen sections of tumor xenografts were treated 
with the purified rat anti-mouse CD31 antibody (BD 
Pharmingen Cat# 550274, × 100 dilution) and Alexa 
Fluor 594 goat anti-rat IgG (Invitrogen, x 2,000 dilution) 
as described previously [43].
Analysis of prognoscan, breastmark, and TCGA 
data
The relationship between LY6E expression and 
overall survival in cancer patients was evaluated by an 
analysis of the PrognoScan [44] and BreastMark [45] 
databases. Briefly, patients were divided into two groups 
according to LY6E expression levels in their tumors at all 
possible cut-off points. The risk differences of any two 
groups were then calculated by the log-rank test. The cut-
off point giving the most significant P value was selected 
and demonstrated in the present study. The TCGA dataset 
is described in [27] and was downloaded from the TCGA 
data portal site (https://gdc.cancer.gov) for the next 
analysis.
Ethics of research using animals
All animal experiments were approved by the 
Animal Research Committee of Kyoto University, and 
performed according to guidelines governing animal care 
in Japan.
Statistical analyses
The significance of differences between 2 
independent subjects was determined using the Student’s 
t-test. A P value < 0.05 was considered to be significant.
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